Literature DB >> 25071107

Musculoskeletal pain in patients with chronic myeloid leukemia after discontinuation of imatinib: a tyrosine kinase inhibitor withdrawal syndrome?

Johan Richter1, Stina Söderlund2, Anna Lübking3, Arta Dreimane4, Kourosh Lotfi4, Berit Markevärn5, Anders Själander6, Susanne Saussele7, Ulla Olsson-Strömberg2, Leif Stenke8.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2014        PMID： 25071107     DOI： 10.1200/JCO.2014.55.6910

Source DB:  PubMed          Journal:  J Clin Oncol        ISSN： 0732-183X            Impact factor:   44.544


× No keyword cloud information.
  42 in total

1.  Research in the heart of hematology: chronic myeloid leukemia 2017.

Authors:  Rüdiger Hehlmann
Journal:  Haematologica       Date:  2017-03       Impact factor: 9.941

2.  Up-regulated exosomal miRNA-140-3p in CML patients with musculoskeletal pain associated with discontinuation of tyrosine kinase inhibitors.

Authors:  Michiyo Asano; Tomohiro Umezu; Seiichiro Katagiri; Chiaki Kobayashi; Tetsuzo Tauchi; Moritaka Gotoh; Keiko Ando; Seiichi Okabe; Junko H Ohyashiki; Kazuma Ohyashiki
Journal:  Int J Hematol       Date:  2017-02-14       Impact factor: 2.490

Review 3.  Present results and future perspectives in optimizing chronic myeloid leukemia therapy.

Authors:  Angelo M Carella; Giuseppe Saglio; Xavier F Mahon; Michael J Mauro
Journal:  Haematologica       Date:  2018-06       Impact factor: 9.941

Review 4.  Current status of ABL tyrosine kinase inhibitors stop studies for chronic myeloid leukemia.

Authors:  Shinya Kimura
Journal:  Stem Cell Investig       Date:  2016-08-09

Review 5.  Chronic Myeloid Leukemia-the Promise of Tyrosine Kinase Inhibitor Discontinuation.

Authors:  Ravi Kishore Narra; Kathryn E Flynn; Ehab Atallah
Journal:  Curr Hematol Malig Rep       Date:  2017-10       Impact factor: 3.952

Review 6.  Quality of Life and Long-Term Therapy in Patients with Chronic Myeloid Leukemia.

Authors:  Kathryn E Flynn; Ehab Atallah
Journal:  Curr Hematol Malig Rep       Date:  2016-04       Impact factor: 3.952

Review 7.  Treatment-free remission in CML: who, how, and why?

Authors:  Francois-Xavier Mahon
Journal:  Hematology Am Soc Hematol Educ Program       Date:  2017-12-08

Review 8.  Treatment-free remission in patients with chronic myeloid leukemia.

Authors:  Delphine Rea; Jean-Michel Cayuela
Journal:  Int J Hematol       Date:  2017-07-08       Impact factor: 2.490

9.  Imatinib withdrawal syndrome and longer duration of imatinib have a close association with a lower molecular relapse after treatment discontinuation: the KID study.

Authors:  Sung-Eun Lee; Soo Young Choi; Hye-Young Song; Soo-Hyun Kim; Mi-Yeon Choi; Joon Seong Park; Hyeoung-Joon Kim; Sung-Hyun Kim; Dae Young Zang; Sukjoong Oh; Hawk Kim; Young Rok Do; Jae-Yong Kwak; Jeong-A Kim; Dae-Young Kim; Yeung-Chul Mun; Won Sik Lee; Myung Hee Chang; Jinny Park; Ji Hyun Kwon; Dong-Wook Kim
Journal:  Haematologica       Date:  2016-02-17       Impact factor: 9.941

Review 10.  Treatment-Free Remission: a New Therapeutic Goal in Chronic Myelogenous Leukemia.

Authors:  Ahmed Gamal Elsayed; Roma Srivastava; Muhammad Omer Jamil
Journal:  Curr Oncol Rep       Date:  2017-10-07       Impact factor: 5.075
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.